Calidi Biotherapeutics Stock Quote CLDI - Stock Price, News, Charts, Message Board, Trades

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

1.47

Bid

Ask

Volume

1,438,677

1.27 Day's Range 1.49

0.73 52 Week Range 18.50

Market Cap

19.225M

Previous Close

1.45

Open

1.35

Last Trade

78453

1.36

Last Trade Time

Financial Volume

$ 2,009,520

VWAP

1.3968

Average Volume (3m)

1,633,691

Shares Outstanding

13,078,022

Dividend Yield

PE Ratio

-0.60

Earnings Per Share (EPS)

-2.23

Revenue

Net Profit

-29.22M

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the price and yield performance of the FLAGLSX-Forensic Accounting Long-Short Index. The investment seeks to provide investment results that, before fees and expenses, correspond generally to the price and yield performance of the FLAGLSX-Forensic Accounting Long-Short Index.

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.calidibio.com

Headquarters

Wilmington, Delaware, USA

Founded

Calidi Biotherapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the American Stock Exchange with ticker CLDI. The last closing price for Calidi Biotherapeutics was $1.45. Over the last year, Calidi Biotherapeutics shares have traded in a share price range of $ 0.73 to $ 18.50.

Calidi Biotherapeutics currently has 13,078,022 shares outstanding. The market capitalization of Calidi Biotherapeutics is $18.96 million. Calidi Biotherapeutics has a price to earnings ratio (PE ratio) of -0.60.

Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer

SAN DIEGO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted...

Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock

SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted...

Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock

SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of...

Calidi Biotherapeutics Announces Proposed Public Offering

SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of...

Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results

Announced FDA Clearance of the Northwestern University IND Application for NeuroNova (CLD-101) Clinical Trial in High-Grade Glioma.Presented data supporting RTNova (CLD-400), the company’s...

Calidi Biotherapeutics to Present Data Supporting RTNova at Upcoming Scientific Conferences

- RTNova, an innovative systemic antitumor enveloped virotherapy, unlocks new possibilities in cancer therapy - RTNova addresses challenges posed by untargetable and untreatable metastatic...

Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement

SAN DIEGO, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of...

NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Calidi Biotherapeutics, Inc. (CLDI WS)

SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted...

Calidi Biotherapeutics Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade Glioma

Trial will evaluate multiple doses of CLD-101 for the treatment of newly diagnosed high-grade glioma CLD-101 is Calidi’s novel allogeneic immunotherapy utilizing neural stem cells to deliver...

Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results

Launched Nova Cell subsidiary with $2 million investment from Dr. Ronald Rigor to advance Calidi’s Adult Adipose Allogeneic (AAA) stem cell innovative programs Strengthened team with the...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.42	-22.2222222222	1.89	1.89	1.34	1155086	1.69613806	CS
4	-0.65	-30.6603773585	2.12	2.3025	1.34	1096097	1.94081956	CS
12	0.31	26.724137931	1.16	3.89	0.73	1633691	2.14062261	CS
26	-0.441	-23.0769230769	1.911	3.89	0.73	966583	2.03458057	CS
52	-16.63	-91.8784530387	18.1	18.5	0.73	1031807	2.72499358	CS
156	-43.63	-96.7405764967	45.1	50	0.73	823345	3.11339893	CS
260	-43.63	-96.7405764967	45.1	50	0.73	823345	3.11339893	CS

CLDI - Frequently Asked Questions (FAQ)

What is the current Calidi Biotherapeutics share price?

The current share price of Calidi Biotherapeutics is $ 1.47

How many Calidi Biotherapeutics shares are in issue?

Calidi Biotherapeutics has 13,078,022 shares in issue

What is the market cap of Calidi Biotherapeutics?

The market capitalisation of Calidi Biotherapeutics is USD 18.96M

What is the 1 year trading range for Calidi Biotherapeutics share price?

Calidi Biotherapeutics has traded in the range of $ 0.73 to $ 18.50 during the past year

What is the PE ratio of Calidi Biotherapeutics?

The price to earnings ratio of Calidi Biotherapeutics is -0.6

What is the reporting currency for Calidi Biotherapeutics?

Calidi Biotherapeutics reports financial results in USD

What is the latest annual profit for Calidi Biotherapeutics?

The latest annual profit of Calidi Biotherapeutics is USD -29.22M

What is the registered address of Calidi Biotherapeutics?

The registered address for Calidi Biotherapeutics is CORPORATION TRUST CENTER, 1209 ORANGE ST, NEW CASTLE, WILMINGTON, DELAWARE, 19801

What is the Calidi Biotherapeutics website address?

The website address for Calidi Biotherapeutics is www.calidibio.com

Which industry sector does Calidi Biotherapeutics operate in?

Calidi Biotherapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
MGLDMarygold Companies Inc	$ 2.053 (48.77%)	128.45k
MINFT Limited	$ 7.25 (44.22%)	948.89k
CTMCastellum Inc	$ 0.578 (41.01%)	8.94M
KULRKULR Technology Group Inc	$ 2.885 (28.79%)	75.72M
MSTUT Rex 2X Long MSTR Daily Target ETF	$ 12.49 (22.81%)	64.96M
BATLBattalion Oil Corporation	$ 1.3499 (-44.56%)	1.63M
NVOXDefiance Daily Target 2x Long Nvo ETF	$ 11.5991 (-35.47%)	407.1k
UVIX2x Long VIX Futures ETF	$ 3.83 (-29.07%)	70.61M
TPETTrio Petroleum Corp	$ 1.10 (-25.17%)	2.81M
MSTZT Rex 2X Inverse MSTR Daily Target ETF	$ 19.235 (-23.06%)	21.33M
SPYSPDR S&P 500	$ 591.15 (0.86%)	122.49M
SPXSDirexion Daily S&P 500 Bear 3X Shares New	$ 6.1628 (-3.25%)	114.87M
SOXLDirexion Daily Semiconductor Bull 3X Shares	$ 27.30 (3.80%)	108.08M
TSLZT Rex 2X Inverse Tesla Daily Target ETF	$ 2.435 (7.27%)	94.23M
KULRKULR Technology Group Inc	$ 2.885 (28.79%)	75.72M